Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Shares Gap Up to $0.74

Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $0.78, but opened at $0.74. Ampio Pharmaceuticals shares last traded at $0.73, with a volume of 60,457 shares changing hands.

Separately, Roth Capital initiated coverage on shares of Ampio Pharmaceuticals in a research note on Thursday, December 19th. They issued a “buy” rating and a $4.00 target price for the company.

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) last issued its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter.

Several hedge funds have recently modified their holdings of the company. Traynor Capital Management Inc. boosted its holdings in Ampio Pharmaceuticals by 67.3% during the fourth quarter. Traynor Capital Management Inc. now owns 91,251 shares of the specialty pharmaceutical company’s stock worth $53,000 after purchasing an additional 36,693 shares during the last quarter. LPL Financial LLC acquired a new position in Ampio Pharmaceuticals during the second quarter worth $34,000. Millennium Management LLC boosted its holdings in Ampio Pharmaceuticals by 207.5% during the third quarter. Millennium Management LLC now owns 149,537 shares of the specialty pharmaceutical company’s stock worth $74,000 after purchasing an additional 100,902 shares during the last quarter. Morgan Stanley boosted its holdings in Ampio Pharmaceuticals by 532.1% during the second quarter. Morgan Stanley now owns 150,025 shares of the specialty pharmaceutical company’s stock worth $58,000 after purchasing an additional 126,291 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in Ampio Pharmaceuticals during the second quarter worth $166,000.

About Ampio Pharmaceuticals (NYSEAMERICAN:AMPE)

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee.

See Also: Outstanding Shares, Buying and Selling Stocks

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.